Chronic rhinosinusitis (CRS) is an important ENT pathology which affects about 5–12% of
the general population. The treatment of CRS can be pharmacological (nasal sprays …

Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a
significant impact on the quality of life (QoL). It is typically characterized by a type 2 …

Type 2 inflammation is characterized by overexpression and heightened activity of type 2
cytokines, mediators and cells that drive neuroimmune activation and sensitization to …

Chronic rhinosinusitis is a heterogenous and multifactorial disease, characterized by
persistent inflammation of the nose and paranasal sinuses, which causes nasal obstruction …

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a high prevalent and burdensome
disease for individuals and health systems which management involves many specialties …

The field of chronic rhinosinusitis (CRS) is constantly evolving. In the past 10 years, key
advancements in basic and translational research as well as clinical studies have improved …

Background Guidelines recommend that the vast majority of patients with severe
uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) should have at least one …

Background Increasing evidence supports the united airway disease (UAD) concept for the
management of upper and lower respiratory diseases, particularly in patients with asthma …

Heterogeneity in outcomes used in clinical trials prevents meta-analysis and contributes to
research waste. Core outcome sets aim to address this by defining a small number of …

Introduction Chronic rhinosinusitis (CRS) comprises several heterogenous groups, now
classified based on endotype more often than on phenotype. A number of studies aimed at …